Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 2, 2019
Daily News
December 2, 2019
- Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
- MHLW Panel OKs Eisai’s Insomnia Med, Fycompa’s Monotherapy and More
December 2, 2019
- Satralizumab Reduces Risk of NMOSD Relapses: Chugai
December 2, 2019
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
- Use of Antibiotics in Japan Down 10.6% in 2018 vs. 2013: MHLW
December 2, 2019
- Boehringer Innovation Chief Touts R&D Efforts on Undruggable Cancer Targets
December 2, 2019
- Santen Starts Voluntary Recall of Pivalephrine
December 2, 2019
- Takeda Submits Niraparib for Ovarian Cancer in Japan
December 2, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…